Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Capital Leases: 2024-2025

Historic Capital Leases for Axsome Therapeutics (AXSM) over the last 2 years, with Sep 2025 value amounting to $4.7 million.

  • Axsome Therapeutics' Capital Leases rose 58.59% to $4.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.7 million, marking a year-over-year increase of 58.59%. This contributed to the annual value of $2.9 million for FY2024, which is N/A change from last year.
  • Per Axsome Therapeutics' latest filing, its Capital Leases stood at $4.7 million for Q3 2025, which was up 23.42% from $3.8 million recorded in Q2 2025.
  • In the past 5 years, Axsome Therapeutics' Capital Leases ranged from a high of $4.7 million in Q3 2025 and a low of $1.7 million during Q1 2024.
  • Moreover, its 2-year median value for Capital Leases was $3.0 million (2024), whereas its average is $3.3 million.
  • Data for Axsome Therapeutics' Capital Leases shows a peak YoY surged of 116.85% (in 2025) over the last 5 years.
  • Over the past 2 years, Axsome Therapeutics' Capital Leases (Quarterly) stood at $2.9 million in 2024, then surged by 58.59% to $4.7 million in 2025.
  • Its Capital Leases stands at $4.7 million for Q3 2025, versus $3.8 million for Q2 2025 and $3.7 million for Q1 2025.